The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.
The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.
Transcript
The use of real-world evidence has been seen as a way to rapidly expand indications for existing therapies without the cost of a new phase 3 trial. What are the pros and cons of this approach?
So, I think when you look at it from the perspective of a health plan, the research, the real-world evidence, provides potential future impacts when it comes to clinical decision making, such as formulary, management, utilization, management, tier placement, etc. While we have also noticed with the real-world evidence that there are perceived barriers, you know, with a timeliness experience with the data, sometimes potential for bias, there's also many perceived benefits that we see. So, it gives us increased data about subpopulations, diverse populations, patient-reported outcomes, health care resource utilization costs, and really helps us formulate our coverage strategy based on the additional data.
With real-world evidence, and its potential for future impact, it informs safety monitoring…also helps with formulary and utilization management, and then, you know, really gives us a better idea of how it's really, for lack of better way of saying it, how it's really working in the patient outside of the study design, right? Well, that's a very controlled environment.
Real-world evidence is viewed as a way to capture data from populations that have traditionally been hard to enroll in clinical trials. Is this a valid approach, or should researchers redouble outreach efforts in communities that are underrepresented in trials?
Well, I think that there's still an opportunity that researchers should reach out and secure those subpopulations or diverse populations for trials. But in many trials, if that's not available, or they don't have the opportunity to do that, then I do think that the real-world evidence does give us insight into those subpopulations and diverse populations. As I mentioned previously, I think that is a benefit of real-world evidence.
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More